GlaxoSmithKline pays $3bn to settle dispute over rosiglitazone and other drugsBMJ 2011; 343 doi: https://doi.org/10.1136/bmj.d7234 (Published 07 November 2011) Cite this as: BMJ 2011;343:d7234
- Nigel Hawkes
GlaxoSmithKline is to pay a record $3bn (£1.9bn; €2.2bn) to settle longstanding disputes with the US government over marketing of some of its best known drugs.
The disputes, some of which go back to 1997, include an investigation by the US Justice Department into the marketing of the antidiabetes drug rosiglitazone (marketed as Avandia) and GSK’s alleged attempts to market the antidepressant bupropion (Wellbutrin) as a slimming aid. The settlement also includes the alleged misuse of “nominal pricing” arrangements to overcharge the Medicaid programme.
Comparison with other large fines levied by the US authorities is difficult, because so many different drugs are involved in the GSK case, but the amount it is prepared to pay exceeds the previous highest levied at one …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial